Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Schuler

Showing results (291-300 of 300) with videos related to

Pageof 30
Sort By:
You have reached the last page of results.This site can display upto 300 results.
International Journal of Cancer|April 20, 2018
Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomasHenning Reis, Kristan E van der Vos, Christian Niedworok, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 12, 2023
Early Detection of Lung Cancer Using Small RNAsTobias Sikosek, Rastislav Horos, Franziska Trudzinski, et al.
Journal of Hematology & Oncology|July 10, 2026
Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumorsIgnacio Melero, María de Miguel, Elena Garralda Cabanas, et al.
Lancet (London, England)|April 16, 2019
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
European Journal of Epidemiology|April 5, 2023
Profile of the multicenter cohort of the German Cancer Consortium's Clinical Communication PlatformDaniel Maier, Jörg Janne Vehreschild, Barbara Uhl, et al.
Nature|March 14, 2024
Evolutionary trajectories of small cell lung cancer under therapyJulie George, Lukas Maas, Nima Abedpour, et al.
Nature|February 25, 2025
Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumoursIgnacio Melero, Maria de Miguel Luken, Guillermo de Velasco, et al.
Nature Medicine|January 6, 2025
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trialJuanita Lopez, Thomas Powles, Fadi Braiteh, et al.
Nature|December 11, 2024
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumoursIgnacio Melero, Maria de Miguel Luken, Guillermo de Velasco, et al.
Nature|July 14, 2015
Comprehensive genomic profiles of small cell lung cancerJulie George, Jing Shan Lim, Se Jin Jang, et al.
Pageof 30

Showing results (291-300 of 300) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 300 results.
International Journal of Cancer|April 20, 2018
Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomasHenning Reis, Kristan E van der Vos, Christian Niedworok, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 12, 2023
Early Detection of Lung Cancer Using Small RNAsTobias Sikosek, Rastislav Horos, Franziska Trudzinski, et al.
Journal of Hematology & Oncology|July 10, 2026
Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumorsIgnacio Melero, María de Miguel, Elena Garralda Cabanas, et al.
Lancet (London, England)|April 16, 2019
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
European Journal of Epidemiology|April 5, 2023
Profile of the multicenter cohort of the German Cancer Consortium's Clinical Communication PlatformDaniel Maier, Jörg Janne Vehreschild, Barbara Uhl, et al.
Nature|March 14, 2024
Evolutionary trajectories of small cell lung cancer under therapyJulie George, Lukas Maas, Nima Abedpour, et al.
Nature|February 25, 2025
Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumoursIgnacio Melero, Maria de Miguel Luken, Guillermo de Velasco, et al.
Nature Medicine|January 6, 2025
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trialJuanita Lopez, Thomas Powles, Fadi Braiteh, et al.
Nature|December 11, 2024
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumoursIgnacio Melero, Maria de Miguel Luken, Guillermo de Velasco, et al.
Nature|July 14, 2015
Comprehensive genomic profiles of small cell lung cancerJulie George, Jing Shan Lim, Se Jin Jang, et al.
Pageof 30